FDA clears Mode Sensors’ wearable for fluid monitoring: Can Re:Balans redefine hospital care?

Why is the FDA clearance of Mode Sensors’ Re:Balans system being viewed as a digital health milestone?

The U.S. Food and Drug Administration has cleared the Re:Balans fluid monitoring system developed by Mode Sensors, an Oslo-based medical device startup. With this 510(k) regulatory approval, Mode Sensors can now market the Re:Balans wearable to healthcare providers across the United States for real-time fluid status monitoring in adult patients. It’s a breakthrough that could fundamentally change how hospitals manage fluid overload, dehydration, and post-operative recovery in high-risk populations such as those undergoing dialysis, cardiac procedures, or advanced age-related care.

Although Mode Sensors is not yet publicly listed, its growing visibility in digital health circles, investor discussions, and clinical adoption conversations has placed it among the top medtech startups to watch in 2025. The company is reportedly raising a Series A funding round to support manufacturing scale-up and commercial rollout, with European CE-mark approval expected in early 2026. As a result, Mode Sensors now joins a short list of sensor-driven medtech firms poised to enter mainstream hospital infrastructure.

The Re:Balans device uses thoracic bio-impedance technology to measure electrical resistance across the chest region, offering a continuous, non-invasive method to monitor fluid balance. For hospitals that currently rely on subjective assessments or sporadic blood testing, this device introduces a potential leap in both precision and operational efficiency.

How does Re:Balans differ from traditional fluid management methods used in hospitals?

Fluid management in hospitals has long been an imprecise, manually intensive, and risk-prone part of patient care. Traditional methods typically involve tracking input and output volumes, conducting regular weight checks, ordering bloodwork, and interpreting physical signs like swelling or shortness of breath. These approaches are laborious and reactive, often resulting in delayed recognition of fluid-related complications such as dehydration or pulmonary edema.

Mode Sensors’ Re:Balans system disrupts this legacy workflow with a continuous, real-time view of a patient’s fluid status. By monitoring thoracic bio-impedance—a physiological signal directly tied to hydration levels—Re:Balans can identify shifts in fluid status early, before visible symptoms manifest. This allows clinicians to intervene proactively, rather than after a patient deteriorates.

In terms of form factor, the Re:Balans wearable is designed to be minimally obtrusive, suitable for extended inpatient use, and capable of integrating with clinical dashboards. This paves the way for a future where fluid status is charted like a vital sign, with nurse staff able to access real-time hydration data as easily as heart rate or blood pressure.

What is the commercial opportunity for wearable fluid monitoring, and why are investors paying attention?

The addressable market for hospital-based fluid monitoring spans multiple high-cost care domains, including nephrology, cardiology, perioperative care, geriatrics, and even oncology. Experts estimate the global opportunity for fluid management-related technologies to be in the billions of dollars annually, particularly when downstream cost savings—reduced ICU stays, fewer readmissions, and improved outcomes—are factored in.

Mode Sensors is well-positioned to tap into this market with a differentiated offering that combines wearability, real-time data collection, and hospital-grade clinical validation. In its public statements, the company has highlighted strong interest from large healthcare players and strategic partners. The ongoing Series A raise is expected to accelerate manufacturing, sales partnerships, and global market entry.

Moreover, the business model is likely to align with modern medtech trends—device-plus-subscription structures, integration with electronic medical records (EMRs), and value-based purchasing tied to patient outcomes. If Re:Balans can demonstrate clinical ROI across multiple sites, Mode Sensors may attract partnerships with hospital networks or become an acquisition target for firms seeking to expand their digital health portfolios.

How does Mode Sensors compare to other players in hospital-grade wearable technology?

The wearable health monitoring space has grown rapidly over the past five years, but most devices have focused on consumer wellness (step counts, heart rate) or chronic disease management outside the hospital. Few companies have targeted fluid monitoring as a primary indication—let alone one cleared by the FDA for inpatient use.

While firms like BioIntelliSense and EarlySense have made inroads into continuous vital-sign tracking, they have yet to bring a commercial-grade fluid-status wearable to market. Similarly, while larger companies like Baxter International and Medtronic have explored sensor platforms, thoracic bio-impedance in a wearable form factor remains rare.

Mode Sensors thus finds itself in a strategically valuable position. It is early in a high-need segment, with a clinically validated, regulator-approved device that solves a known pain point in hospital workflows. If it can build out its ecosystem—data dashboards, alert systems, integration APIs—it could capture a sticky foothold in hospital IT and care coordination layers.

However, Mode Sensors will face competition as others enter the space. Larger players with stronger distribution and regulatory teams may seek to replicate or acquire similar technologies. As such, execution speed and clinical outcomes in early deployments will be critical in cementing Re:Balans as the gold standard.

How might Re:Balans impact hospital operations and patient outcomes if widely adopted?

The promise of Re:Balans lies in its ability to convert fluid monitoring from an intermittent task into a continuous clinical metric. This shift could reduce nurse workload, minimize errors from manual charting, and enable earlier intervention in patients at risk of deterioration.

Hospitals that adopt Re:Balans could potentially decrease ICU admissions triggered by fluid imbalance, shorten post-operative recovery times, and lower readmission rates for heart failure and dialysis patients. All of these improvements contribute directly to quality scores, patient satisfaction metrics, and reimbursement outcomes under value-based care models.

Additionally, fluid imbalance is increasingly recognized as a driver of morbidity in elderly and immunocompromised patients, making hydration management a target for precision care programs. If Re:Balans integrates successfully with hospital information systems, it could become part of automated alerting systems that recommend adjustments to IV therapy or diuretics based on dynamic trends—not guesswork.

What are the next strategic steps for Mode Sensors after FDA clearance?

Mode Sensors has outlined a clear roadmap: begin commercial deployment in U.S. hospitals, secure CE marking for European expansion by Q1 2026, and scale production capacity to meet early demand. The Series A funding round, currently underway, is expected to play a pivotal role in financing this expansion while ensuring inventory reliability and onboarding support.

Early-stage partnerships will likely focus on nephrology units, cardiac wards, and surgical recovery centers—areas where fluid management is mission-critical. Demonstrating improved patient outcomes, lower readmission rates, and reduced ICU costs in these settings will be vital for long-term adoption.

At the same time, Mode Sensors will need to expand its sales team, invest in customer success infrastructure, and provide clinical training materials to ensure smooth onboarding across care teams. If these pieces fall into place, Mode Sensors could evolve from a single-device company into a platform player in real-time physiological monitoring.

Key takeaways: Why Mode Sensors’ Re:Balans may be the start of a new era in fluid monitoring

• The U.S. FDA has granted 510(k) clearance to Mode Sensors’ Re:Balans wearable system for non-invasive, real-time fluid status monitoring in adults.

• The device uses thoracic bio-impedance to provide continuous hydration data, potentially transforming fluid management across hospitals.

• The target markets include dialysis, heart failure, surgical recovery, and elderly care—areas where fluid imbalance contributes to morbidity and cost.

• Mode Sensors is raising a Series A round and preparing for commercial rollout in U.S. hospitals, with EU approval expected by early 2026.

• The company enters a largely uncontested space, with few hospital-grade wearables focused on fluid status monitoring currently on the market.

• Successful deployment could reduce nurse workload, lower readmissions, and enhance value-based care outcomes.